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AbstrACt
Introduction Recent failures of potential novel 
therapeutics for Alzheimer’s disease (AD) have prompted 
a drive towards clinical studies in prodromal or 
preclinical states. However, carrying out clinical trials 
in early disease stages is extremely challenging—a 
key reason being the unfeasibility of using classical 
outcome measures of dementia trials (eg, conversion to 
dementia) and the lack of validated surrogate measures 
so early in the disease process. The Deep and Frequent 
Phenotyping (DFP) study aims to resolve this issue 
by identifying a set of markers acting as indicators of 
disease progression in the prodromal phase of disease 
that could be used as indicative outcome measures in 
proof-of-concept trials.
Methods and analysis The DFP study is a repeated 
measures observational study where participants will 
be recruited through existing parent cohorts, research 
interested lists/databases, advertisements and memory 
clinics. Repeated measures of both established (cognition, 
positron emission tomography (PET) imaging or 
cerebrospinal fluid (CSF) markers of pathology, structural 
MRI markers of neurodegeneration) and experimental 
modalities (functional MRI, magnetoencephalography 
and/or electroencephalography, gait measurement, 
ophthalmological and continuous smartphone-based 
cognitive and other assessments together with 
experimental CSF, blood, tear and saliva biomarkers) will 
be performed. We will be recruiting male and female 
participants aged >60 years with prodromal AD, defined 
as absence of dementia but with evidence of cognitive 
impairment together with AD pathology as assessed using 
PET imaging or CSF biomarkers. Control participants 
without evidence of AD pathology will be included at a 1:4 
ratio.
Ethics and dissemination The study gained favourable 
ethical opinion from the South Central—Oxford B NHS 
Research Ethics Committee (REC reference 17/SC/0315; 
approved on 18 August 2017; amendment 13 February 
2018). Data will be shared with the scientific community 
no more than 1 year following completion of study and 
data assembly.
IntroduCtIon 
Prevention of Alzheimer’s disease (AD) is 
the single most important unmet need in 
medicine today; a common disorder with 
increasing prevalence in an ageing society 
that has huge personal and financial impact 
on individuals, families and societies1 and yet 
without any disease-modifying therapy. The 
estimated global prevalence of 34 million 
patients for dementia as a whole in 2010, is 
expected to double every 20 years (to approxi-
mately 66 million by 2030 and to 115 million by 
2050) due to an ageing population worldwide 
and improved diagnosis.2 Trials of potential 
therapeutics conducted in people with estab-
lished disease have failed,3 prompting a drive 
strengths and limitations of this study
 ► Participants will be phenotyped repeatedly using es-
tablished biomarkers of Alzheimer’s disease    (AD) 
pathology (cognition; positron emission tomography 
and cerebrospinal fluid markers of pathology; struc-
tural MRI markers of neurodegeneration) as well as 
a number of experimental biomarkers.
 ► A comprehensive pilot study demonstrated that the 
proposed depth and frequency of phenotyping is 
feasible across six clinical sites and is acceptable 
to volunteers despite including invasive procedures 
such as lumbar puncture and being very demanding 
on participant time.
 ► The study data will be made available to the 
scientific community within one year of the 
study's completion.
 ► The engagement and involvement of stakeholders 
including the Alzheimer’s Society and members of 
the public proved essential in conducting a success-
ful pilot and will considerably enhance the conduct 
and outcome of the main study.
 ► The study size has been determined from power cal-
culations and modelling but remains small.
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towards clinical studies in prodromal (mild symptoms 
not amounting to dementia) or preclinical (evidence of 
disease in absence of symptoms) states where interven-
tion might be expected to be more effective.4 However, 
clinical trials in such early disease states, with minimal or 
no symptoms, face two critical challenges; how to identify 
people with disease processes before symptoms become 
apparent and how to measure outcomes of interventions. 
The first of these—selection of people with preclinical 
or prodromal disease—has been made possible by the 
availability of pathology markers such as positron emis-
sion tomography (PET) imaging or cerebrospinal fluid 
(CSF) biochemistry, although there remain logistical and 
other challenges before such markers become routine 
outside of the context of clinical research. Second, and 
perhaps more challenging, is the difficulty of assessing 
the impact of therapeutics in clinically silent or minimally 
symptomatic trial participants. While study designs using 
progression to dementia as an outcome are appropriate 
for efficacy trials, such approaches are necessarily long 
and large and therefore extraordinarily demanding and 
correspondingly expensive; prohibitively so for proof-of-
concept phase trials. The absence of indicative outcome 
measures suitable for relatively short proof-of-concept 
trials is therefore an undoubted limitation in the field, and 
acts as an impediment on early phase drug development.
The Deep and Frequent Phenotyping (DFP) study 
is designed to address the challenges of prodromal AD 
intervention development by generating a biomarker set 
for proof-of-concept studies early in the disease process. 
Multiple biomarker studies are currently underway 
including the Alzheimer’s Disease NeuroImaging Initia-
tive (ADNI) in the USA,5 Australian Imaging, Biomarker 
& Lifestyle Study of Ageing,6 AddNeuroMed in Europe7 
and ADNI-like cohorts are being conducted globally. 
In Europe, many such studies are being aggregated for 
combined analysis in the IMI-European Medical Infor-
mation Framework ( www. emif. eu). However, almost all 
such biomarker studies use relatively infrequent assess-
ments and the assessments employed focus on well-estab-
lished markers, such as structural imaging and molecular 
markers of known pathological processes.
The DFP study will combine both established and 
novel markers. Specifically, the study will implement PET 
imaging and CSF biochemistry for beta-amyloid (Aβ) 
plaques and tau neurofibrillary tangles, functional and 
structural MRI, electrophysiology for synaptic function 
including electroencephalograhy (EEG) and magneto-
encephalography (MEG), measures of retinal pathology 
and a collection of biosamples for molecular biomarkers 
and to establish induced pluripotent stem cells (iPSCs) 
for in vitro studies. The study will therefore create the 
single largest cohort in prodromal AD individuals who 
have been characterised using such a wide variety of 
complex biomarker measures. It will also generate a 
comprehensive biological sample set, that when linked 
to the biomarker measures, will provide a platform for 
future translational neuroscience studies. Finally, the 
study will aim to take advantage of the rapidly developing 
information technology field to develop methods for 
monitoring cognition using smartphone and wearable 
technology. We will deploy smartphone-based cognitive 
applications to provide frequent testing aimed at identi-
fying individual-specific memory extinction curves. The 
study will also test the utility of wearable devices to capture 
gait, navigational ability (indoor and outdoor) as proxies 
for cognitive ability and functional state. These methods 
have the potential to provide the high granularity, ecolog-
ically valid and intraindividual data that are likely to be 
required to detect subtle cognitive and functional change 
at scale in the trial-ready cohorts of the future.
The DFP study builds on the infrastructure of Demen-
tias Platform UK (DPUK; https://www. dementiasplat-
form. uk/): recruitment will be facilitated through 
DPUK’s information workstream for recontacting partici-
pants from its constituent cohorts and pre-existing DPUK 
imaging and biobank data on DFP participants will be 
used wherever possible. Recruitment will take advantage 
of the investment made in the UK in NIHR Biomed-
ical Research Centres that are part of the Translational 
Research Collaboration for Alzheimer’s Disease. Finally, 
the study will take the lead from ADNI and its partner 
studies, making trial data readily available to the scientific 
community.
deep and Frequent Phenotyping: a pilot study
Recognising the challenges of a study of such high inten-
sity, we undertook a pilot DFP study to assess its feasibility 
and acceptability. From a feasibility perspective, the study 
worked to establish the operational practicability of a 
very extensive and repeated phenotyping over 6 months 
across six centres. Predetermined criteria for feasibility 
success included the implementation of all 10 phenotype 
measures with >80% completion rate in each and that data 
from any given modality was of at least equivalent quality 
to that when implemented alone in a single site (defined 
by variance). The pilot study recruited its first participant 
in December 2014 and the last study assessment took 
place in January 2016. The study screened 32 participants 
with the aim of recruiting 24 (4 per clinical site). Eight 
participants were excluded at screening: five as they failed 
to meet study entry criteria, one because of having had a 
recent PET scan, one for withdrawal of consent and one 
for an unspecified reason. Twenty-two participants were 
included after screening (due to two sites being unable 
to recruit the target number of participants in the study 
window) and 20 remained at 6-month follow-up (one 
participant withdrew consent after week 12 and one was 
excluded after baseline visit due to psychosis not reported 
at screening). The study protocol included all the assess-
ments proposed in the current study. Completion rates 
for the different assessments ranged from 76% to 100% 
as follows: clinical assessments (100%), conventional (ie, 
pen and paper) and computerised cognitive assessment 
(100%), gait assessment (94%), ophthalmological assess-
ment (86%), CSF collection (76%), blood collection 
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(95%), MRI neuroimaging (89%), neurophysiology 
assessment (81%). Working protocols for each modality 
were produced by modality leads to ensure consistency 
across centres and where data were successfully acquired 
it was of a high standard. Specifically, quality control for 
each modality demonstrated:
1. Clinical assessments: clinical assessments were per-
formed at the baseline visit at all sites. Minimal errors 
in test completion were identified during monitoring 
visits and were successfully rectified.
2. Cognitive assessments: all sites performed cognitive 
testing with conventional assessments at baseline and 
day 169 while computerised assessments took place 
at screening and the four assessment visits. Training 
was required for use of the Cambridge Neuropsycho-
logical Test Automated Battery (CANTAB) test and 
this was provided by the manufacturer (Cambridge 
Cognition). Minimal completion errors in conven-
tional testing were identified and successfully rec-
tified. Data loss from the computerised battery was 
3.6%.
3. Ophthalmology: participants had retinal imaging at 
three locations on two occasions: before day 85 and 
day 169. No training or scheduling issues were iden-
tified. Data loss was 14% due to a participant being 
unable to complete the task and further three partic-
ipants having partial data collections due to difficulty 
fixating their gaze. Quality control did not reveal sig-
nificant issues.
4. Gait: gait was assessed using body-worn tri-axial accel-
erometers at all sites in laboratory settings at baseline 
and day 169 as well as in free-living conditions for 7 
days from day 85. Research assistants required training 
in the use of accelerometers and this was provided by 
the lead site for gait (Newcastle). Data loss was mini-
mal (3.2%) and the received data was of high quality.
5. Blood and urine collection: blood and urine were col-
lected at all sites using standard protocols (available on 
request) while peripheral blood mononuclear cell pro-
cessing protocols required nursing staff training that 
was arranged locally. Insufficient quantity of blood for 
the purposes of the study was obtained in only 1% of 
samples. iPSC lines were successfully generated from 
18 individuals.
6. CSF collection: lumbar punctures (LPs) were per-
formed at study baseline and day 169 at all sites. Sched-
uling issues led to 4 LPs not taking place and a further 
4 LPs were cancelled for medical reasons (two instanc-
es where LP was medically unfeasible and two where 
the LP at day 169 was declined due to severe headache 
following baseline LP).
7. MRI scanning: the design included four scans (two 
on sequential days during the baseline assessment ep-
isode, one at day 29 and one at day 85) at all sites. No 
training issues were identified. Seven per cent of scans 
did not take place due to scanner availability. The ac-
quired images were reported to be of good quality with 
no significant intersite variability.
8. Neurophysiology: participants underwent EEG and 
MEG scans at four sites during the baseline assessment 
episode. No training requirements were identified. 
Twelve per cent of the scans did not take place due 
to scanner availability and 5% of the data was incom-
plete (participants unable to tolerate full length of the 
scans). Data quality was found to be of good quality 
with no significant intersite variability.
PET neuroimaging is a critical component of the 
proposed study and its feasibility was piloted on a single 
occasion before day 85 of the study at one study site only 
(Invicro, formerly known as Imanova). This excluded all 
four participants from the Newcastle site for logistical 
reasons. Of the 17 participants eligible for PET amyloid 
and tau neuroimaging, 16 completed amyloid scanning 
and 15 underwent tau scanning. One amyloid imaging 
scan was cancelled due to logistical reasons while two tau 
imaging scans did not take place (one participant declined 
to have the procedure and another scan was cancelled for 
logistical reasons). Amyloid PET data from one further 
participant was unusable due to excessive motion (88% 
complete data) and tau PET data from three participants 
were not used due to insufficient time spent in scanner 
(71% usable data).
The total completion data per modality is presented 
in figure 1. Based on a completion rate of >80% across 
modality and excellent quality control, the study met its 
criteria for feasibility success.
The acceptability of the study to participants was 
assessed using questionnaires, a focus group and follow-up 
interviews conducted by the Alzheimer’s Society. Ques-
tionnaire data were collected at study end from 91% of 
all participants. The questionnaire asked participants to 
indicate the level of pleasantness or comfort that they 
experienced for each of the measures and provided 
opportunities for participants and their study partners to 
provide suggestions for improvements in the full study. 
The questionnaire also directly asked participants if they 
would be willing to enter a similar study and all ques-
tionnaire completers responded positively. The majority 
of participants expressed a sense of pride that they were 
doing something to benefit others. The rest of the ques-
tionnaire responses indicated a high degree of accept-
ability on all measures, reporting their overall experience 
in the study as ‘good’ or ‘excellent’, including the LP 
procedure.
A poststudy focus group took place at Alzheimer’s 
Society with two members of the DFP team, Alzhei-
mer’s Society and three participants from different sites 
(one participant attended with their study partner). Six 
follow-up interviews were also carried out by Alzheimer’s 
Society on the telephone, two of which were attended 
by a study partner. These activities provided qualitative 
confirmation of the acceptability and gave specific recom-
mendations for the main study that were implemented 
in its design (more flexibility for the role of study part-
ners, shortening the length of the PET scan and ensuring 
appointments are booked well in advance wherever 
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possible). The qualitative research undertaken also rein-
forced the acceptability of LPs, with all but one partici-
pant saying it was much more comfortable than feared.
These acceptability results met predefined success 
criteria defined as >80% of participants willing to enter a 
similar study, >50% expressing willingness to proceed to 
a full study and there being no more than four drop-outs.
This pilot study highlighted several issues ranging from 
the optimal acquisition ordering of imaging protocols to 
avoid scan artefacts, to the optimal time of day for the 
various measures taking the participants’ comfort into 
account. Working with this information and in collab-
oration with our user group, it was possible to improve 
processes, shorten timings of assessment and reduce 
patient burden, building in protocol flexibility where 
necessary. In summary, this pilot study demonstrated 
that a complex protocol including both complex assess-
ments and measures perceived as invasive can be effec-
tively established across multiple sites. Furthermore, the 
trial participants were sufficiently committed to remain 
engaged throughout the duration of the study, despite 
the demands of the study. In the full study, we will 
continue to partner with the Alzheimer’s Society who will 
lead on the generation of participant information mate-
rials, including explanatory videos, and we will continue 
to work with the Alzheimer’s Society lay panel to monitor 
study progress. We will in addition incorporate an ethical, 
social and legal implications workstream using qualitative 
research methodology to understand participant engage-
ment and burden as well as explore the participants’ 
understanding and tolerability of processes related to 
biomarkers and precision medicine.
MEthods And AnAlysIs
study design
This is a multicentre (eight recruitment centres across 
the UK), non-interventional, repeated measures, observa-
tional design study in approximately 250 male and female 
participants aged ≥60 years with prodromal AD, defined 
as absence of dementia but with evidence of cognitive 
impairment together with AD pathology assessed using 
PET and/or CSF methods as well as control participants 
lacking cognitive impairment and without evidence of AD 
pathology, in a 4:1 ratio.
Repeated measures of both outcome comparator 
(cognition and pathology) and assessment modalities will 
be taken for most modalities at baseline and follow-up 
and at defined time points during the study and, for 
some measures continuously, over a period of 12 months. 
Modalities to be measured include: PET imaging and 
CSF biochemistry for amyloid and tau; functional and 
structural MRI; electrophysiology for synaptic function, 
including EEG and MEG; measures of gait and use of 
remote monitoring for assessment of a range of pheno-
types; measures of retinal pathology and collection of 
biosamples.
The selection of these modalities is influenced by the 
decision to recruit participants with prodromal AD; the 
need to represent the full range of behavioural, functional 
Figure 1 Summary of completed assessments per modality. CSF, cerebrospinal fluid; EEG, electroencephalograhy; 
MEG, magnetoencephalography; PET, positron emission tomography. 
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and cognitive impairments arising from AD; the need to 
use established assessments used in historical and current 
clinical trials, as well as exploratory assessments and the 
operational practicability of these modalities established 
in the pilot DFP study.
The rationale for the frequency of assessments for each 
modality is discussed in more detail in each modality 
section below and is titrated to the evidence and likely 
value of repeated measures. For example, very frequent 
repeated measures for MRI is proposed first as there is 
evidence of value in 24 hours repeats to enhance signal 
to noise and second as repeated measures at 3 months 
have shown change in AD, yet the optimal frequency of 
imaging to measure change has not yet been demon-
strated. For CSF sampling, only three assessment points 
are proposed, as there is less evidence for change within 
a year.
A schedule of assessments is given in table 1.
Participants with an absence of AD pathology assessed 
using PET amyloid or CSF Aβ levels, who are not selected 
to enter the study, will be invited to participate in a 
substudy involving smartphone-based cognitive testing 
(Mezurio smartphone application) over a 12-month 
period. These participants will undergo a follow-up visit at 
the end of the testing period (clinical assessments, body 
fluid sampling and CANTAB cognitive testing). We antici-
pate to recruit 150 participants in this substudy.
study objectives and outcome measures
The primary objective of the study is to identify a marker 
set from data from a wide range of assessment modalities 
that tracks disease change. Modalities include markers 
of structure and function derived from MRI, markers 
of synaptic function derived from electrophysiology 
(EEG and MEG) and markers from innovative methods 
including assessment of retinal pathology and both 
gait, cognition and activity from wearable devices and 
connected technology together with biosamples. These 
samples will be made available for future studies using 
metabolomics, genomics, proteomics, transcriptomics 
and other approaches. We plan to meet the primary 
objective by using measurements of a change in compar-
ator modalities of pathology (PET or CSF measures) or 
change in cognition.
The study’s secondary objective is to identify a marker 
set from summary data from a wide range of assessment 
modalities that predicts disease change. The comparator 
measure for this objective would be measurement of a 
change in cognition and transition from prodromal to 
disease phase at 1 year and beyond.
Participant selection
The study aims to recruit male and female subjects 
aged >60 years with prodromal AD, defined as absence of 
dementia but with evidence of AD pathology as assessed 
using PET or CSF (ie, amyloid-positive individuals or 
AmyPos); and amyloid-negative subjects (AmyNeg) 
without AD pathology on PET imaging or CSF analysis, in 
a 4:1 ratio. Inclusion and exclusion criteria for this study 
are presented in online supplementary materials.
In order to identify such individuals we will use a 
screening funnel approach, with multiple steps, seeking 
people that have agreed to be approached for research 
participation from research cohorts, those signed up to 
research databases and from memory clinics. To reduce 
screen failure when trying to identify AmyPos and 
AmyNeg individuals in a 4:1 ratio, we will use existing data 
including cognitive scores and family history of dementia 
where it exists, such as when seeking participants from 
cohort studies. In regard to the cognitive scores we will 
define subclinical impairment as being in the range 
between 1 and 1.5 SD below the mean for the test used in 
the respective cohort. Where there is no recent cognitive 
data available, we will ask cohorts to select on age and 
family history and invite those participants. In the second 
step we will then ask those participants that respond to 
complete a brief cognitive test online (CANTAB Paired 
Associates Learning [PAL] Task), via the study website 
( www. dfpstudy. co. uk). Enrolment will include people 
with subclinical cognitive impairment (defined as scores 
ranging between 1 and 1.5 SD below the mean for the 
age-adjusted and sex-adjusted mean of the cognitive test) 
and no apparent impairment (defined as scores in the 
range between 0.5 and 1 SD below the mean) in a 4:1 
ratio, in part to avoid disclosure of cognitive state. Where 
there is no suitable prior information, such as in some 
research-willing registers or in direct approaches to the 
public through social media and advertisement, we will 
invite people within the age range of the study and with a 
family history of dementia to complete the same online-
based prescreening methods. Potential participants 
attending memory clinics with a diagnosis of mild cogni-
tive impairment, who express interest in participating in 
research, may also be approached if they meet criteria.
In the final step of the screening funnel, people identi-
fied through the process described above will be invited 
to attend a screening appointment where inclusion and 
exclusion criteria will be reviewed and apolipoprotein E 
(APOE) status will be established (either through consent 
to access parent cohort data on APOE or providing sample 
for APOE genotyping). An APOE-4-enriched cohort (ie, 
4:1 ratio of APOE carriers vs APOE non-carriers) will be 
invited to a second screening appointment where cere-
bral amyloid status will be determined using PET imaging 
or CSF sampling. Final inclusion in the study will be based 
on amyloid positivity at a ratio of 4:1. A summary of partic-
ipant selection is provided in figure 2.
study procedures
Participants will be interviewed with a semi-structured 
clinical assessment for sociodemographic and lifestyle 
factors, and family history of AD/dementia in first-degree 
relatives. We will record medical history and medication, 
together with measurements of height, weight, waist-
to-hip ratio and blood pressure. Assessment of cognition 
and function will include Mini Mental State Examination, 
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Amsterdam Instrumental Activities of Daily Living ques-
tionnaire, The Brain Injury Screening Questionnaire, 
the National Adult Reading Test, the Mild Behavioural 
Impairment Scale, together with the Clinical Dementia 
Rating. The assessments will also include Geriatric 
Depression Scale, State-Trait Anxiety Inventory and Pitts-
burgh Sleep Quality Index.
Cognition
For the purposes of website-based cognitive screening 
(where pre-existing cognitive scores are not available), we 
will use a browser-optimised version of the PAL task that is 
part of CANTAB (Cambridge Cognition). PAL total error 
scores will be used to define cognitive impairment (scores 
between 1 and 1.5 SD below the age-adjusted and sex-ad-
justed mean) and no apparent cognitive impairment 
(scores between 0.5 and 1 SD below the age-adjusted and 
sex-adjusted mean) for the purposes of inviting partici-
pants to the first screening appointment. The PAL scores 
will be deleted once this information has been used 
to determine which participants will be invited to the 
screening appointments.
In the main study, cognition will be assessed using two 
batteries of cognitive tests. At baseline, 6 months and at 
1 year, the protocol for assessment of cognition estab-
lished for the IMI-European Prevention of Alzheimer’s 
Disease (EPAD) study will be implemented. This protocol 
was established by an expert working group8 and consists 
of:
 ► Reaction Time/Information Processing Speed/
Conceptual Shifting/Selective Attention including 
the Eriksen Flanker Task (NIH EXAMINER/Toolbox) 
and Coding (RBANS);
 ► Verbal Episodic Memory including List learning 
(RBANS) and Story Memory (RBANS);
 ► Visuospatial Analysis including Figure Copy (RBANS) 
and Semantic Fluency (RBANS);
 ► Working Memory including Digit Span (RBANS) and 
Dot Counting (NIH Examiner);
 ► Allocentric Spatial Memory: Four Mountains Task 
(UCL/University of Cambridge);
 ► Paired-Associate Learning: Name-Face Pairs (UCSF);
 ► Navigation in Egocentric Space: Virtual Reality Super-
market Trolley (UCL).
In addition, a tablet-based cognitive test battery using 
the CANTAB (Cambridge Cognition)9–11 will also be 
implemented at the following time points: screening, 
baseline, day 30, day 60, day 240 and day 300. This battery 
focusses on five neuropsychological domains: attention, 
episodic memory, processing speed, working memory 
and executive function, identified by the National Insti-
tute of Health Cognitive Toolbox as being the core deter-
minants of functioning and independence.
The CANTAB battery consists of:
 ► Rapid visual processing task (attention and processing 
speed);
 ► PAL task (episodic memory);
 ► Reaction time task (processing speed);
 ► Spatial working memory task (working memory and 
executive function).
The tablet-based CANTAB battery was successfully 
used in the pilot DFP study at five time points. A short 
Figure 2 Summary of participant selection. AD, Alzheimer’s disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; 
DFP, Deep and Frequent Phenotyping.
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questionnaire after each testing session ascertained ease 
of use from the subjects’ perspective. Interim analysis of 
the data showed that the cognitive tests produced results 
consistent with expected levels of performance in this 
population and the data received were comparable across 
sites. All of the tests had a completion rate of between 
95% and 100%, with the battery overall having a comple-
tion rate of 97%.
PET imaging
PET Aβ tracers have been established over the last decade 
and Amyvid, Neuraceq and Vizamyl have been approved 
by the US Food and Drug Administration and Euro-
pean Medicines Agency. Radiotracers made available in 
recent years (such as [18F]AV-1451, [18F]MK-6240 and 
[18F]PI-2620) enable in vivo imaging of tau pathology 
deposits.12 13 Initial data from these tracers has demon-
strated a tau signal, which increases when moving from 
healthy controls, through MCI and into AD.14 15 Under-
standing the relationship between Aβ and tau during the 
earliest phase of the disease is likely to be critical for the 
successful development of therapies.
PET Aβ will be the primary method for screening 
participants. Where for logistical reasons CSF Aβ was used 
instead of PET Aβ for screening, a single PET Aβ scanning 
will be completed at any point during the study. A subset 
of 100 subjects will have both Aβ and tau scans at baseline 
and at 12 months follow-up. For each PET scan, partici-
pants will receive an intravenous injection of the appro-
priate radiotracer with data acquisition in the region of 
20–30 min (depending on tracers) following an uptake 
period appropriate for the particular radioligand and its 
kinetics. All PET scans will be performed as outpatient 
procedures on either a PET/CT or PET/MR scanner. In 
terms of radiation exposure participants will undertake 
a maximum of four PET scans over the course of the 
study, with a maximal injected dose of 150 MBq per scan. 
The exposure varies between participants depending on 
which PET tracers they receive, whether they undergo 
Aβ screening or Aβ and tau tracer PET imaging with 
follow-up PET scans, and to a lesser extent whether they 
undergo PET/MR or PET/CT imaging. The total effec-
tive dose therefore varies between 2.8 mSv (for a single 
Amyvid PET-MR scan) and 15.0 mSv (for Neuraceq and 
[18F]AV-1451 PET-MR scans and potential attenuation 
correction CT scans at baseline and follow-up). These 
doses are equivalent to about 1.5 and 6.5 years of average 
background radiation in the UK respectively and have 
been chosen to provide acceptable image quality while 
minimising the total radiation exposure.
Data will be analysed centrally, as in the pilot study, 
including image-based motion correction, region of 
interest definition and generation of regional stan-
dardised update ratio values (SUVR). Parametric SUVR 
images in stereotaxic space for voxel-wise analyses will also 
be generated. Aβ positivity will be determined automati-
cally based on the whole cortex SUVR value according 
to literature-based threshold for that tracer. Higher-level 
study analyses will then be performed in image space to 
explore the relationship between Aβ and tau, the change 
in protein densities over time and their relationship to 
other clinical assessments and biomarkers.
Magnetic resonance imaging
Advances in image acquisition and analysis of MRI 
now facilitate a diagnosis of AD at a predementia (eg, 
mild cognitive impairment) stage and have been used 
to monitor change in interventional studies. This is 
recognised in the incorporation of imaging into interna-
tional diagnostic guidelines for AD and prodromal AD.16 
In particular, measures of whole brain and hippocampal 
atrophy have been shown to precede symptoms by several 
years and longitudinal imaging provides power to detect 
change in these early cases.17
MRI will be performed on five occasions: day 1, days 
2–5, day 60, day 180 and day 365. In some centres, it 
may be possible to combine baseline MRI with screening 
PET, reducing the overall scan time. The MR acquisi-
tion protocol will consist of the EPAD core sequences 
(ADNI 3-matched volumetric T1-weighted imaging, 3D 
T2-FLAIR, axial T2-weighted and T2*-weighted imaging), 
and a set of more advanced sequences: 3-shell HARDI 
diffusion-weighted imaging with b=300, 1000, 2000 s/
mm2, resting state functional MRI, quantitative suscepti-
bility mapping (QSM) and arterial spin labelling (ASL) to 
provide measures of macrostructural and microstructural 
loss and functional network disruption.
Analysis of the serial MR imaging protocol will be 
similar to that used in the pilot DFP study, comprising 
measures of:
 ► Macrostructural change derived from volumetric 
T1-weighted imaging with within-subject registra-
tion and quantification including global atrophy 
rates (whole brain and ventricular volume), regional 
(hippocampal) atrophy rates and cortical thickness 
and template-based regional (parcellation) atrophy 
and data-driven model-dependent analyses of shape 
change across multiple grey matter regions.
 ► Microstructural pathology and loss of connectivity—
change in grey and white matter diffusivity (DWI-de-
rived fractional anisotropy, axial and radial diffusivity).
 ► Connectivity and change in network status (from rest-
ing-state fMRI).
 ► Vascular burden and microhaemorrhages—secondary 
to both atherosclerotic and amyloid angiopathy (eg, 
derived from FLAIR, T2-weighted and QSM).
 ► Perfusion and arterial arrival times from ASL.
The total scan time per visit will be approximately 
1 hour.
To model physiological noise and instrument variability, 
baseline data will be acquired twice as previously estab-
lished as a noise reduction paradigm,18 followed by closely 
spaced assessments (day 60 and day 180) to establish the 
lower limit of MRI temporal sensitivity and at day 365. 
Assessment of the day 365 scan will benefit from multi-
level modelling of within-subject and between-subject 
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variance for each of the biomarkers, such that rates of 
change (eg, of atrophy) will be specified more precisely. 
In combination with parallel initiatives (eg, ADNI 3), this 
will allow sample size estimates for clinical trials over a 
range of intervals to be determined.
Neurophysiology
Changes in Aβ and tau lead to remodelling and loss of 
synapses and microcircuits, with impaired synaptic func-
tion and plasticity-dependent learning and memory.19 
It is widely hypothesised that synaptic loss and dysfunc-
tion precedes the neuronal death that eventually results 
in gross structural changes seen in MRI. The study will 
determine whether the impact of peri-symptomatic AD 
pathology on synapse function and circuits is identifiable 
using MEG-EEG.
All subjects will undergo two MEG/EEG sessions (base-
line and 1 year) and a subset (based on centre capacity) 
may undergo a third session at 8 months. At each session, 
the experimental measures will be standardised, and 
include:
 ► Acute plasticity supporting predictive coding of 
sensory regularities, probed by an auditory mismatch 
negativity task;
 ► Evoked and induced MEG/EEG signatures of multi-
modal associative learning;
 ► Evoked and induced MEG/EEG signatures of scene 
repetition learning;
 ► Evoked and induced MEG/EEG signatures of an 
audio-visual-motor task;
 ► Visual evoked gamma in posterior cortex;
 ► Resting-state indices of large-scale network dynamics, 
including (a) partial directed coherence of MEG/
EEG and (b) fast transient dynamics and variability in 
large-scale brain networks.
The MEG/EEG scans will be performed in the same 
order, with up to 60 min of recording in a series of short 
‘tasks’ each lasting 5–20 min, including:
 ► Simple audio-visuo-motor task: participants press a 
button quickly in response to a simple black and white 
visual stimulus presented on screen together with an 
auditory tone.
 ► Scene repetition task: a series of landscape scenes are 
viewed on screen, some of which are repeated after a 
variable interval. The participant is asked to look out 
for an occasional prespecified target (an image of the 
moon), and press a button when this is seen.
 ► Cross modal learning: the participant views a series of 
objects on screen, which are paired with an associated 
tone. The learnt associations between object and tone 
are revealed by low frequency presentations of novel 
tones and of mismatching object-tone pairs.
 ► Resting eyes open: participants will be instructed to 
relax and look gently at a fixation cross.
 ► Auditory mismatch-negativity task: a brief auditory 
threshold paradigm is run and the main task tones 
are adjusted to be 60 dB above the estimated audi-
tory threshold. The auditory mismatch presents 
variable short ‘beep’ tones every 500 ms. No response 
is required of the participant, who may view a natural 
history film without sound to maintain wakefulness 
and reduce tiredness.
Wearable technology and connected devices
Wearable technology and connected devices are defined 
as devices worn on the body or embedded into mobile 
phones, watches, bracelets, etc. While such technology 
has become pervasive and is increasingly used by the 
general public, there are few examples of its effective use 
in dementia research to date. There is much promise 
that such devices could be sensitive to subtle changes 
in cognition and provide opportunities for unobtrusive 
monitoring in the participants’ own environment. An 
important goal therefore for the DFP study is to assess the 
ability of such devices to measure behaviours or pheno-
types as potential measures of change in prodromal AD 
alone or in combination with established or experimental 
assessments.
Quantifying gait using wearable technology
Gait is increasingly recognised as an important tool to 
inform diagnostic algorithms, track disease progression 
and measure the efficacy of interventions in a range of 
neurodegenerative diseases, including AD.20 In the pilot 
DFP study, we deployed a body-worn tri-axial accelerom-
eter for detailed gait analysis in the clinic and unobtrusive 
monitoring of gait and activity during free living.21 Partic-
ipants with AD showed a more variable gait in the clinic 
than during free living which by contrast revealed differ-
ences for temporal features of gait. These preliminary 
results indicate a subtle but important effect of environ-
ment or habitual behaviour which will be examined in 
full in this study.
Gait will be assessed on three occasions in the clinic 
and through 7-day home monitoring at baseline, day 180 
and day 365. For home monitoring, the monitor will be 
attached during the clinical visit and worn for 7 days, after 
which time it will be returned. Assessment of gait in the 
clinic will include a validated single and dual-task gait 
protocol that takes approximately 30 min to administer, 
using a small, lightweight and waterproof accelerometer. 
Assessment of gait in the home will involve participants 
wearing the accelerometer on their lower back for 7 days. 
Gait outcomes will be derived from a theoretical model 
and will include a range of outcomes known to be sensi-
tive to cognition.
Continuous assessment of function and cognition using mobile 
technologies
Three complementary methodologies will be deployed 
across the DFP sites to explore and identify cognitive 
and/or functional change longitudinally: cognitive smart-
phone assessments; localisation methodology using smart-
watches and brief mood and sleep assessments. All data 
will be anonymised. Several of these approaches require 
the participant to have an iOS or Android smartphone. 
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Where participants do not have such a device it will be 
provided.
i. Mezurio smartphone application
The Mezuirio smartphone application is a collection 
of cognitive tasks designed for relevance to AD. Inte-
grated within a single application are tasks targeting: 
episodic memory, semantic memory, executive function, 
language, visuospatial ability and speed of processing. All 
tasks are scheduled within a single application to simplify 
the installation process and user-interface. Interactions 
with the tasks within Mezurio are positioned at approxi-
mately monthly intervals, with more concentrated testing 
sessions at baseline and in the final month of the study. 
The maximum anticipated duration of engagement with 
each task across the trial is shown in table 1.
Pseudonymised data collected from the app will auto-
matically upload to secure study servers hosted by Oxford 
University Medical Sciences IT Services with anonymised 
summary data then being periodically uploaded via a 
secure manual procedure to the DPUK portal.
ii. Sea Hero Quest
Sea Hero Quest (http://www. seaheroquest. com/) is a 
tablet or smartphone-based virtual reality test to examine 
spatial navigation and orientation behaviour. The game 
has been played by over 2.7 million people, generating 
over 73 years of gameplay, making it the largest dementia 
study in history. The gameplay presents participants with 
different navigational challenges, including i) wayfinding 
(ie, navigating to different checkpoints based on initially 
presented map information); ii) path integration (ie, 
navigating to a waypoint from where the player launches 
a flare towards the starting point of navigation); iii) radial 
maze (ie, maze navigation according to the landmarks 
or internally generated information). All tasks measure 
different combinations and delineation of allocentric and 
egocentric navigation behaviour. Participants only play 
selected levels of the game.
We will ask participants to consider playing Sea Hero 
Quest as part of their involvement in this study. This will 
be an optional task. We will ask participants to play the 
game at least once during their participation in DFP, 
for at least 15 min. This will provide enough data for 
comparison against average performance in existing data-
sets. Data transfer from Sea Hero Quest to DFP will be 
processed to be pseudonymised and no personal identifi-
able information will be exchanged.
iii. Localisation system
We will deploy methods from the emerging field of 
Positioning Systems to provide a continuous view of 
participants’ movement and activity within and outside of 
their homes. In terms of indoor positioning, this novel 
method solves the problem of insufficient indoor satel-
lite coverage and limited use of handsets indoors and 
provides information on patterns of activity within the 
day, indoor walking speed and time spent within specific 
rooms. We plan to generate a pattern of activity within 
the home for each participant and during the 6 months 
of indoor positioning data recording (first 6 months of 
the study or day 1 to day 178), we will seek to identify 
deviations from this pattern as early signs of deterioration 
in function. Mobile outdoor tracking will be recorded 
throughout the 12-month study period and will capture 
GPS data outside of the home, to test the hypothesis that 
the disruption of entorhinal cortex and hippocampal 
function in early AD will cause progressive disintegration 
of the ‘cognitive map’, identifiable on analysis of everyday 
spatial navigational behaviour.
We will deploy commercially available smartwatches for 
high-frequency movement data collection. Participants 
will be encouraged to charge the smartwatch every night, 
and then carry the device with them as soon as they get up. 
Participants will be given 4–6 Bluetooth mains powered 
beacons, which should be distributed within specific 
rooms of their homes (eg, living room, kitchen, etc). This 
will create fixed navigational points for the smartwatch to 
wirelessly identify. The smartwatch data will be automati-
cally uploaded anonymously and with encryption when in 
range of known wireless internet to a secure server hosted 
by the Oxford Department of Computer Science. Mobile 
outdoor tracking will be recorded through an application 
installed on participant’s smartphones. It will track GPS 
location and inertial sensor data which will tell us about 
their movements outside the home. The app will period-
ically synchronise with the secure study servers over the 
participants’ wireless internet. Anonymised data from 
the indoor and outdoor tracking applications will be 
uploaded to the Dementias Platform UK wearable devices 
portal via a secure manual procedure.
From indoor positioning data we will derive a summary 
of indoor domestic movements (eg, proportion of time 
spent at various rooms, instances of room re-entry), infer-
ences about the type of activity over a period (eg, sitting, 
walking, cooking, etc) and characteristics of those activi-
ties (eg, in-home walking speed). We will identify a pattern 
of activity within home-based daily routines on an indi-
vidual participant level using a sequence matching algo-
rithm and will seek to identify deviations from this pattern 
longitudinally as a marker of functional deterioration.
Outdoor navigational behaviour will be analysed at 
differing levels of complexity, ranging from simple 
measures (eg, numbers of destinations visited) through 
to low level topological (eg, note degree, average path 
length) and higher level topological (eg, clustering coef-
ficient, local and global efficiency metrics).
Mood and sleep diary
Using an app developed by the University of Oxford, 
we will collect information about participants sleep and 
mood at different points of the day. Brief ratings scales 
will be used to assess individual mood components, 
and sleep quality and duration. To minimise the partic-
ipant setup burden, these Mood and Sleep tasks will be 
deployed within the Mezurio app described above. Data 
will be uploaded through a cloud-based transit layer 
(which will comply with UK Data Protection Act stan-
dards) then be held on servers hosted by the Oxford 
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University Medical Sciences IT Services, and managed 
by the Oxford Cognitive Health and Neurosciences Clin-
ical Trials Unit. Analysts will use both tools developed in 
Oxford, and tools hosted outside Oxford which comply 
with the UK Data Protection or US-EU privacy shield. All 
summary measures resulting from these analyses will be 
uploaded to the Dementias Platform UK wearable devices 
using secure manual procedures. Raw diary data will be 
destroyed once summary measures have been finalised.
Ophthalmological assessment
Recent evidence from dementia studies has demonstrated 
changes in retinal nerve fibre layer and overall retinal 
thickness, retinal vascular calibre in the macular area22 
as well as the appearances, and progression of extracel-
lular deposits under the retinal pigment epithelium of 
the peripheral retina.23
In this study, we will combine basic assessments of 
visual acuity at the time of recruitment with structural 
retinal imaging and tear collection in both eyes. Changes 
in the central and peripheral retina will be assessed by 
Ultra-Wide Field Imaging (UWFI) using a laser scanning 
ophthalmoscopy (OPTOS). Colour and autofluorescent 
images will be used to assess extracellular deposit forma-
tion, cell atrophy and vascular changes both in the macula 
and the periphery.23 24 In addition, optical coherence 
tomography (OCT) images will be generated to assess 
changes in nerve fibre and other retinal layers around the 
papilla as well as in the macula, and to measure changes in 
the choroidal thickness.25 Tear collection samples will be 
stored at −80°C and use for proteomics26 and metabolo-
mics27 at a later stage. The acquisition of UWFI and OCT 
images and tear collection will take 30 min in total. The 
ability to non-invasively detect retinal amyloid load is an 
exciting additional possibility.28 We will use an approach 
developed by Neurovision Imaging utilising laser scan-
ning ophthalmoscopy to detect amyloid deposits in the 
human retina. The imaging for amyloid index will add a 
further 30 min to the imaging protocol.
Ophthalmological assessments will be carried out at 
baseline (days 1–5), day 180 and day 365. Subjects will be 
dilated with tropicamide after tear collection and before 
imaging to enhance image quality and field of view. 
Therefore, the total assessment period will take approx-
imately 60 min. Following their acquisition, anonymised 
images will be transferred to the CARF image analysing 
centre at Queen’s University Belfast, and finally grading 
results will be incorporated into the DFP database.
Molecular markers
Cerebrospinal fluid
The pilot DFP study demonstrated that repeated LP for 
CSF is practicable and acceptable to elderly people in the 
UK, especially when performed with fine gauge needle 
aspiration. A CSF collection and processing protocol 
widely used in clinical studies29 was adapted for use in the 
pilot DFP study. Seventy-six per cent of LPs were success-
fully conducted. On two occasions subjects declined to 
have their second LP because of experiencing headache 
at the first CSF collection. A further two could not be 
completed for medical reasons. Four LPs were omitted 
due to logistics and not participant acceptability problems.
In this study, LP will be performed at baseline, at day 
180 and at day 365. We will measure Aβ and tau, using 
the best available assay, at a central laboratory and in 
addition aliquots of CSF will be stored for future explor-
atory studies. A maximum of 10 mL of clear CSF will be 
collected on each occasion in accordance with local safety 
procedures.
Blood, saliva and urine
Sample storage will be centralised at an established 
national resource centre following processing and 
aliquoting. Sample storage will meet the highest stan-
dards for sample safety and preservation, and compliance 
with requirements of the Human Tissue Act. Samples 
including blood, CSF, urine and saliva will be made avail-
able to DFP study investigators and the wider scientific 
community via a sample access committee for use in 
future research projects that have appropriate approvals 
in place. We anticipate applications to use this valuable 
sample using untargeted methodologies for exploratory 
studies such as proteomics, metabolomics and genomics 
and targeted methodologies to validate or otherwise 
confirm previous findings from such exploratory studies.
Participant acceptability
Identifying expectations of participation in research is 
particularly pertinent in this study, as there is a signifi-
cant burden on subjects, with important implications for 
recruitment and drop-out.
In the pilot DFP study, subject acceptability was assessed 
by considering recruitment, participation and drop-out 
due to study factors. In addition, a subject engagement 
study was conducted by the Alzheimer’s Society; ques-
tionnaires were designed to be completed by subjects at 
their final study visit, a focus group and six telephone 
interviews were conducted with subjects and their carers. 
A further focus group was held at the end of the study. 
The questionnaire directly asked subjects if they would be 
willing to enter a similar study; all subjects that completed 
a questionnaire answered ‘yes’. Subjects indicated a high 
degree of acceptability on all measures, reporting their 
overall experience as ‘good’ or ‘excellent’. Recommen-
dations for improvements to the study from subjects and 
carers will be incorporated into this study and include: 
more flexibility for the role of carers or study partners 
in the study; shortening the length of the PET scan and 
ensuring that appointments are booked well in advance 
whenever possible.
Understanding the experience of participation in this 
study will contribute to debate on two important issues 
in research. First, this study is representative of a trend 
in biomedical research towards the development of 
‘precision medicine’ platforms based on the deep biolog-
ical profiling of disease processes and it is imperative to 
 o
n
 26 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024498 on 23 March 2019. Downloaded from 
13Koychev I, et al. BMJ Open 2019;9:e024498. doi:10.1136/bmjopen-2018-024498
Open access
understand how participation in such initiatives affects 
subjects and how their experience shapes the research 
process. Second, such work contributes to clarifying 
the concept of ‘participant burden’ in clinical research, 
something that remains ill-defined and poorly under-
stood. This component of the study builds on the pilot 
work highlighted above and work within the ethical, legal 
and social implications work package of DPUK where 
specific scenarios within the DFP study were explored in 
workshops with potential subjects.
In-depth qualitative interviews will be conducted with 
up to 30 participants at two time points: within 14 days of 
the baseline visit and within 14 days of the day 180 visit. 
Interview participants will be approached during periods 
of ethnographic observation at three of the research sites 
(selected to include both rural and urban populations) 
during baseline and day 180 visits. Observation and inter-
view data will provide the foundation for an empirically 
informed assessment of participant’s expectations and 
experiences of participation. This questionnaire will 
explore participation burden with all study participants 
at day 300.
sample size calculation and data analysis plan
Sample size calculation
We performed power calculations estimating the 
numbers needed to identify a biomarker of change 
from summary measures. Assuming that (i) 20% of the 
APOE-enriched prodromal population would show dete-
rioration in cognition at 1 year; (ii) 80% power to detect 
a difference in outcome between those with worsening 
cognitive functioning and those without of at least 0.7 SD 
(or 0.8 or 1) of 1 year change in biomarker values; (iii) 
there are 10 of the biomarker summary values with effect 
sizes of at least 0.7 (or 0.8 or 1) and (iv) a false discovery 
rate of 5% using a two-sided, two sample t-test, then a 
total sample size of 225 (175 or 115) would be required. 
For a single test, the individual significance level is set 
to approximately 0.001. The probability of detecting all 
10 tests where the true standardised effect size is at least 
0.7 (0.8 or 1) is 0.12 (0.13 or 0.14). This calculation is 
in line with observed figures from ADNI, where it can 
be shown that a sample size of 186 is sufficient to detect 
a 25% change in marker values over 1 year in early and 
prodromal AD.30
Therefore, based on power calculations above and 
building on the data from structural imaging we aim to 
include 250 participants, 80% being amyloid positive. 
Such a trial will have sufficient power to detect minimal 
change in established markers in 1 year and therefore 
suitable for identification of biomarkers of greater effi-
cacy. Using the screening algorithm discussed above and 
described in figure 2, we estimate we will need to screen 
360 individuals to achieve this goal.
We may recruit additional participants if some drop out 
to ensure the final number of participants is as close to 
250 as possible.
Data analysis plan
In this section, we broadly describe the statistical methods 
likely to be used in this study in the first wave of anal-
ysis. However, we expect many other approaches to be 
used as the data become available to the wider scientific 
community. As there will be a wealth of data collected 
from various different modalities (imaging to molecular 
markers), our data analysis strategy begins by performing 
separate analyses by modality using the standard suite of 
statistical tools and software developed for these modali-
ties. These analyses will include generating the summary 
(derived) data from the raw data using well recognised, 
tested and/or standardised pipeline/protocol in order to 
extract summary features of importance (eg, regions of 
interest).
First wave analyses will be informed by the pilot DFP 
study and will begin by comparing the average 1-year 
change in biomarkers between those who had a worsening 
in cognitive functioning (or with a change in disease 
state) and those who did not, using only the baseline 
and 1-year measurements of these biomarkers. Cognitive 
functioning will be defined through the cognitive copri-
mary outcome measures of i) adjusted errors on the PAL 
task and ii) between search errors on the spatial working 
memory (SWM) task. Clinically meaningful deteriora-
tion will be defined as a loss of either 3 or 1 points (PAL 
and SWM, respectively) over the 12-month study dura-
tion. While normative performance for PAL and SWM 
has been defined as 0.6 and 0.4 points change per year 
of age, respectively,31 in amyloid-positive and APOE E4 
carriers an average 3-point change in PAL and 1 point in 
SWM has been observed for a sample of MCI patients who 
transition to AD.32 Further investigations into identifying 
a marker set from a wide range of assessment modali-
ties that tracks disease change will use regression meth-
odology (including mixed models and extensions) that 
incorporate change measures and may involve dimen-
sion reduction techniques (eg, principal component 
analysis), variable selection approaches (eg, LASSO and 
Elastic Net) and efficient use of repeated measurements. 
For example, linear mixed effects analyses of the whole 
group on the longitudinal CANTAB composite memory 
score will be used to determine if there are relationships 
with the various markers. Similar regression methodology 
will be used to identify a marker set that predicts disease 
change. Here however, previous measurements of the 
markers will be considered instead of change measures. 
Alternative machine learning methodology for unsuper-
vised and supervised learning, which are now regularly 
used for analysing Big Data problems, will also be used. 
Issues related to missing data, multiple testing, validation, 
correct functional forms of variables, high correlation 
of biomarkers, the potential differing timing pattern of 
biomarkers and cognitive outcomes will be addressed.
Additional analyses include repeatability/reproduc-
ibility of MRI, the interchangeability/calibration of 
CANTAB and EPAD batteries of cognitive tests using the 
baseline data (linked to the inclusion of DFP data from 
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participants who are also part of EPAD into the EPAD’s 
disease modelling) and joint modelling of biomarkers 
(such as between Aβ and tau).
Ethics and dissemination
Subject confidentiality
The study staff will ensure that the subjects’ anonymity 
is maintained. The subjects will be identified only by a 
subject ID number on all study documents and any elec-
tronic database (except for the participant recruitment 
website run by TrialSpark), with the exception of the elec-
tronic Clinical Report Form (eCRF), where subject initials 
may be added. All documents will be stored securely and 
only accessible by study staff and authorised personnel.
Subject data will be deidentified at all times. The study 
will comply with the General Data Protection Regulation, 
which requires data to be anonymised as soon as it is prac-
tical to do so. Measures to maintain confidentiality with 
wearable modality assessments are discussed in 'Ophthal-
mological Assessment' section.
Data monitoring and access
Direct access will be granted to authorised represen-
tatives from the sponsor and host institution for moni-
toring and/or audit of the study to ensure compliance 
with regulations.
Data management
Clinical data collection will be using electronic clin-
ical record forms and this together with summary data 
generated from each of the modalities will be collected 
centrally. Trials management software together with a 
website bespoke to different routes of participant identi-
fication will be used.
Open data sharing
Data sharing between the DFP project and the scientific 
community will be enabled on the Synapse infrastructure 
(Sage Bionetworks, Seattle, USA), no more than 1 year 
following study-team exclusive access to the fully assem-
bled dataset (we anticipate requiring under a year to 
collate and prepare the data for analysis). Synapse oper-
ates under a governance process that includes well-doc-
umented Terms and Conditions of Use, guidelines and 
operating procedures for handling data, data security 
measures with strict information and privacy enhancing 
technologies, as well as the right of audit and external 
reviews (WIRB 20112068). The DFP study consent will 
include agreements for data sharing and will be trans-
parent and explicit in the intent for this study to share 
pseudonymised data within the large multisite study team 
and to share fully anonymised data more widely with the 
scientific community.
Once data curation has completed the data will be made 
available to qualified investigators through a public DFP 
portal that is linked to the DPUK portal. Data access will 
require a data use statement that will be posted together 
with the investigator name and institution on the public 
DFP data release site, enabling others to see how the 
data are being used. The file annotations will facilitate 
the incorporation of data generated through the DFP 
with other AD-related studies hosted in synapse, such as 
data generated through the Accelerating Medicines Part-
nership-Alzheimer’s Disease ( synapse. org/ ampad) and 
the AddNeuroMed study (https://www. synapse. org/#! 
Synapse: syn2790911/ wiki/ 235387).
Neuroimaging data
Imaging data (PET, MRI, MEG) will be collected at each 
site and uploaded in DICOM format directly to the DPUK 
Imaging Informatics infrastructure (https:// info. dpuk. 
org), which is based on the XNAT technology (https://
www. xnat. org). DFP will be set up as a stand-alone 
‘node’ on the central hub, which is physically located at 
the Farr Institute in Swansea. Image analysis pipelines, 
including quality control, will be run either through the 
XNAT infrastructure directly, or by downloading data for 
processing. Imaging-derived phenotypes will be extracted 
and uploaded to central data repository.
Patient and public involvement
Patients and the public were involved in the study design 
through the pilot DFP study. Proceeding with the full 
study was contingent on the pilot demonstrating satis-
factory participant acceptability of such an intensive 
study. Our results showed that there was a high degree of 
acceptability for all measures and that participants would 
have been willing to enter a similar study. In addition, 
we collected feedback on the study procedures through 
questionnaires, poststudy interviews as well as a focus 
group (the latter two conducted in collaboration with 
the Alzheimer’s Society). This led to us change the study 
design to allow more flexibility for the role of study part-
ners, shortening the PET scan duration and ensuring 
appointments are booked as much in advance as possible 
(see Section ‘Deep and Frequent Phenotyping: a pilot 
study’ for more details on this work). For the full study 
we will continue to partner with the Alzheimer’s Society 
for the generation of information materials and videos 
explaining study procedures. We will also seek the Alzhei-
mer’s Society’s lay panel input on monitoring study prog-
ress. Finally, we are planning to incorporate a qualitative 
research workstream aiming to understand participant 
engagement and burden as well as explore the partici-
pants’ understanding and tolerability of processes related 
to biomarkers and precision medicine.
suMMAry
The DFP study is a major collaborative effort as part 
of Dementias Platform UK, bringing together both 
academic and industrial partners aimed at creating the 
most in-depth collection of fluid, clinical, imaging and 
digital biomarkers for prodromal AD. The feasibility and 
acceptability of such intense phenotyping was established 
through a pilot study that was deemed a success through 
predefined criteria. The primary outcomes of the study 
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will provide the means to identify target populations and 
assess outcomes in early phase, proof-of-concept clin-
ical trials in AD more effectively than currently possible. 
Success in doing so would speed up trials, reduce costs, 
increase productivity and ultimately contribute to more 
effective pipelines for early clinical drug development. 
The programme will also generate a rich dataset that 
we intended to make available for use by the scientific 
community.
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